GASTROGRAFIN SUMMARY
Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is a palatable lemon-flavored water-soluble iodinated radiopaque contrast medium for oral or rectal administration only. Each mL contains 660 mg diatrizoate meglumine and 100 mg diatrizoate sodium; pH has been adjusted to 6.0 to 7.6 with sodium hydroxide. Each mL contains approximately 4.8 mg (0.21 mEq) sodium and 367 mg organically bound iodine.
Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous.
Gastrografin may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology.
|
NEWS HIGHLIGHTSMedia Articles Related to Gastrografin (Diatrizoate Meglumine / Diatrizoate Sodium)
The Diagnostic Clinic Introduces A Vaccination Alternative To The Flu Jab
Source: Flu / Cold / SARS News From Medical News Today [2009.11.12]
The Diagnostic Clinic in London's New Cavendish Street, the UK's premier centre for Integrated Medicine, offers a vaccination alternative for private and corporate patients not wishing to have the Flu or Swine Flu jab. Many people have concerns regarding vaccinations. Whether this is as simple as needle phobia or concerns over the safety of vaccinations, an alternative can be considered.
Phadia Introduces New Food Allergy Diagnostic Tools To Meet The Needs Of Allergists
Source: Allergy News From Medical News Today [2009.11.10]
Today at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology, Phadia US introduced two new products designed specifically to meet the unique needs of the nation's 6,000 allergists. ImmunoCAP ISAC and ImmunoCAP HR are new offerings designed to augment traditional allergy testing methodologies and enable diagnosis of complex food allergies at the molecular level, available through its own PiRL testing facility.
New Diagnostic Method For Gout: Dual Energy Computed Tomography Instead Of Joint Aspiration
Source: Gout News From Medical News Today [2009.06.05]
The most reliable method of diagnosing gout is to aspirate the joint in order to obtain fluid to verify the presence of monosodiumurate crystals (uric acid). Up to now, computed tomography (CT) has played a limited role in the evaluation of gout, since conventional CT systems cannot reliably verify deposits of uric acid.
Utility Of Circulating DNA As Novel Diagnostics For Human Cancer, Mad Cow Disease And Other Conditions
Source: CJD / vCJD / Mad Cow Disease News From Medical News Today [2009.03.12]
Chronix Biomedical - developing and applying proprietary techniques to detect and analyze circulating nucleic acid sequences for the diagnosis and management of disease - reported that three recent studies published in peer-reviewed journals have further confirmed the potential diagnostic and prognostic utility of fragments of DNA and RNA that circulate in the blood, known as circulating nucleic acids (CNAs).
Diagnostic Approved to Detect
Source: MedicineNet Clostridium Difficile Colitis Specialty [2009.01.14]
Title: Diagnostic Approved to Detect
Category: Health News
Created: 1/14/2009 2:00:00 AM
Last Editorial Review: 1/14/2009
Published Studies Related to Gastrografin (Diatrizoate Meglumine / Diatrizoate Sodium)
Water-soluble contrast medium (gastrografin) value in adhesive small intestine obstruction (ASIO): a prospective, randomized, controlled, clinical trial. [2008.10]
BACKGROUND: Patients with adhesive small intestine obstruction (ASIO) are difficult to evaluate and to manage and their treatment is still controversial. The diagnostic and therapeutic role of water-soluble contrast medium (Gastrografin) in ASIO is still debated. This study was designed to determine the therapeutic role of Gastrografin in patients with ASIO... CONCLUSIONS: Data showed that the use of Gastrografin in ASIO is safe and reduces the operative rate and the time to resolution of obstruction, as well as the hospital stay.
Water-Soluble Contrast Medium (Gastrografin) Value in Adhesive Small Intestine Obstruction (Asio): A Prospective, Randomized, Controlled, Clinical Trial. [2008.08.08]
BACKGROUND: Patients with adhesive small intestine obstruction (ASIO) are difficult to evaluate and to manage and their treatment is still controversial. The diagnostic and therapeutic role of water-soluble contrast medium (Gastrografin) in ASIO is still debated. This study was designed to determine the therapeutic role of Gastrografin in patients with ASIO... CONCLUSIONS: Data showed that the use of Gastrografin in ASIO is safe and reduces the operative rate and the time to resolution of obstruction, as well as the hospital stay.
Randomized controlled trial of Gastrografin in adhesive small bowel obstruction. [2005.08]
BACKGROUND: Several previous studies have shown that Gastrografin can be utilized to triage patients with adhesive small bowel obstruction (ASBO) to an operative or a non-operative course. Previous studies assessing the therapeutic effect of Gastrografin have been confounded by post-administration radiology alerting the physician to the treatment group of the patient. Therefore the aim of the present paper was to test the hypothesis that Gastrografin hastens the non-operative resolution of (ASBO)... CONCLUSIONS: Gastrografin accelerates resolution of ASBO by a specific therapeutic effect.
Three-dimensional CT enterography using oral gastrografin in patients with small bowel obstruction: comparison with axial CT images or fluoroscopic findings. [2009.09.11]
CONCLUSION: The use of gastrografin for 3D CT enterography is a safe and feasible technique for precise evaluation of known or suspected SBO.
Clinical Impacts of Oral Gastrografin Follow-Through in Adhesive Small Bowel Obstruction (SBO). [2009.05.08]
BACKGROUND: Many studies have shown that gastrografin can be used for diagnosis of adhesive small bowel obstruction (ASBO) and for assessing the need for surgical intervention. However, several studies have reported conflicting results. Therefore, the aim of this study is to assess the diagnostic and therapeutic effect of gastrografin in ASBO... CONCLUSIONS: Oral gastrografin helps in the management of ASBO. Oral gastrografin is safe and reduces the operative rate and time of resolution as well as hospital stay.
Clinical Trials Related to Gastrografin (Diatrizoate Meglumine / Diatrizoate Sodium)
(Gastrografin Use in Small Bowel Obstruction Caused by Adherences) [Completed]
Adhesive small intestine obstruction (ASIO) is an important cause of hospital admission and a
very common disease. Any improvement in this field will benefit many patients by reducing the
operative rate. Patients with this disease are difficult to evaluate and to manage and their
treatment is controversial. Emergency surgery is mandatory when strangulation is suspected or
in the case of total obstruction. On the other hand, conservative non-operative treatment is
indicated in the case of partial obstruction. The role of water-soluble contrast medium
(Gastrografin®: GG) in ASIO is still debated with regard to the therapeutic value.
The aim of our study was to determine the therapeutic role of Gastrografin in patients with
small intestine obstruction without strangulation caused by adherences (ASIO).
Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction [Recruiting]
Small bowel obstructions are responsible for 2 to 5% of emergency hospital admissions and
20% of all emergency surgical procedures. In 60 to 80% of cases, acute small bowel
obstructions are the consequence of intraperitoneal postoperative adhesions. They constitute
an extremely frequent pathology, leading to a high rate of hospital admissions and money
expense.
Management of small bowel obstruction is based on 2 options: either a surgical approach
where all patients are operating on, or a conservative treatment in which surgery is
proposed in case of failure of medical treatment. The surgical approach leads to operate on
an excessive rate of patients while the medical approach increases the risk of increased
small bowel resection, morbidity rate or hospitalization duration.
In order to improve the management of small bowel obstruction, it seems necessary to better
distinguish patients that need an emergency surgical procedure from patients in which
medical treatment will be useful. Many studies have been performed to investigate the value
of imaging in the management of small bowel obstruction, using abdominal X-ray, oral
gastrografin administration or CT-Scan.
The aim of this study is to analyse the effect of a systematic performance of imaging
investigation on the management of patients presenting with a postoperative small bowel
obstruction.
All patients suffering from a postoperative small bowel obstruction will be included in this
study. They will be randomised in 2 groups. In group S, patients will have CT-Scan and oral
water administration while in group SG, Patients will have CT-Scan and oral gastrografin
administration The major end point of this study is to analyse whether imaging examination
can reduce the need for a surgical approach or the rate of small bowel resection and to
determine its influence on fasting time or hospitalization duration
Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT [Recruiting]
Patients who are scheduled by their health care provider for routine CT scan will be asked
to participate in this study. The primary purpose is to determine if there is a difference
in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic
CT. A secondary objective is to evaluate if there is significant difference in bowel
opacification for the two agents.
Topical Pancreatic Duct Lidocaine for Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis [Not yet recruiting]
Safety Study of Autologous Stem Cell in Liver Cirrhosis [Terminated]
It is a fase I/II clinical study to evaluate feasibility, safety and kinetics of cellular
therapy with bone marrow-derived mononuclear cells (ABMMC) in patients with liver cirrhosis.
All the patients have moderate liver disfunction and a waiting time expectancy of liver
transplantation longer than 12 months due their low MELD score. The ABMMC are labeled with
99mTc and infused through the hepatic artery. Scintigraphy is performed 2 and 24 hours after
infusion. Patients are submitted to frequent clinical, laboratorial and image evaluation
during the follow up period of 12 months.
|
